GlassScriptPhysician profile
Sruthi Jinna
NPI 1225479678
$785.88
in general payments reported to CMS, 2019-2025
22 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.83 · 2023: $54.35 · 2024: $16.73 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $101.42 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $78.86 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $76.12 | 2025 | Korlym |
| Radius Health, INC. | $51.21 | 2025 | Tymlos |
| Ibsa Pharma INC. | $45.34 | 2025 | Tirosint, Licart, Flector |
| Dexcom, INC. | $39.72 | 2021-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $39.19 | 2025 | Twiist |
| Novo Nordisk INC | $38.25 | 2021-2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $31.40 | 2025 | Gvoke Hypopen |
| Soleno Therapeutics, INC. | $29.56 | 2025 | Vykat Xr |
| Ascendis Pharma Endocrinology INC | $28.91 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $28.67 | 2025 | |
| Amneal Pharmaceuticals LLC | $24.13 | 2025 | Unithroid |
| Madrigal Pharmaceuticals | $23.94 | 2025 | Rezdiffra |
| Abbott Laboratories | $23.54 | 2025 | Freestyle Libre 3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.93 | 2025 | Tepezza |
| Kyowa Kirin, INC. | $19.24 | 2025 | |
| Antares Pharma, INC. | $19.00 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.71 | 2025 | Jardiance |
| Ipsen Biopharmaceuticals, INC | $17.57 | 2023 | Increlex |
| Tolmar, INC. | $16.08 | 2025 | Jatenzo |
| Lilly USA, LLC | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sruthi Jinna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.